Search
MRK.US:Little scope for competitive labelling for Keytruda in 2nd line lung cancer after new overall
- Amit Roy
- Dec 21, 2015
- 1 min read
Merck published full overall survival results of their phase III KEYNOTE-010 study of anti PD-1 immunotherapy in 2nd line NSCLC (lung cancer) at ESMO Asia this weekend. We present a comparison of Keytruda’s potential label vs competitor Opdivo from Bristol-Myers...
Comments